Skip to main content
OpenTrials
Completed

NCT Number: NCT01129700

Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer

Concurrent chemoradiotherapy (CRT)

* Radiotherapy 25 ㏉/5 fractions (start concomitantly at D1)

* ↓ ↓ ↓ ↓ ↓

* Radical surgery 6 weeks after completion of chemoradiotherapy

* ↑ ↑ ↑ ↑ ↑ D1 - - - - - D5 * 5-Fluorouracil 400㎎/㎡/day + LV 20㎎/㎡/day IV bolus during the radiotherapy

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

National Cancer Center Korea

Goyang-si, Gyeonggi-do, 410-769, South Korea

About this study

Radiotherapy using tomotherapy is delivered in 5 Gy daily fractions for a total of 25 Gy in 5 fractions.

A bolus injection of 5-fluorouracil (400 mg/m2/d)and leucovorin (20 mg/m2/d) is delivered concurrently on day 1-5 during radiotherapy.

Total mesorectal excision is performed within 6±2 weeks. The pathological response of downstaing is the study endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically proven diagnosis of adenocarcinoma of the rectum (located within 8㎝ above the anal verge)
  • Locally advanced and curatively resectable tumor(cT3-4 classification) evaluated with magnetic resonance imaging(MRI) with or without transrectal ultrasonography(TRUS)
  • Age ≥18
  • Performance Status(ECOG) 0-2
  • CBC/differential obtained within 14 days prior to registration on study, with adequate bone marrow function defined as follows: Hemoglobin ≥ 10 g/dl, Absolute neutrophil count(ANC) ≥ 1,500 cells/㎣, Platelets ≥ 100,000cells/㎣
  • Metabolic panel within 14 days prior to registration on study, with adequate liver and renal function defined as follows: AST and ALT ≤ 60 IU/L, bilirubin ≤ 1.5 mg/dl, serum creatinine ≤ 1.5 mg/dl
  • Patient must provide study-specific informed consent prior to study entry

Exclusion criteria

  • Any evidence of distant metastases(M1)
  • Prior invasive malignancy (except non-melanomatous skin cancer and uterine cervical cancer in situ) unless disease free to a minimum of 3 years
  • Hereditary rectal cancer; Familial adenomatous polyposis(FAP), Hereditary non-polyposis colorectal cancer(HNPCC), etc.
  • Impending obstruction (except the case with colostomy)
  • Severe, active comorbidity inappropriate to CRT as follows; Acute bacterial or fungal infection, transmural myocardial infarction within the last 6 months, unstable arrhythmia, angina and/or congestive heart failure, unstable arrhythmia
  • Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception
  • Unresected synchronous colon carcinoma
  • Clinically unresectable rectal cancer

Treatment and study plan

Radiation: short-course preoperative chemoradiotherapy

Radiation

Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).

Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day).

Primary outcomes

  1. To evaluate the pathologic response

    Time frame: After surgery with pathology data

    downstaging(ypT0-2N0M0)rate

Secondary outcomes

  1. Tumor regression grade & MR volumetry

    Time frame: After surgery with pathology data for TRG, at the pretreatment work-up and 1-4 days befor surgery

    To evaluate the tumor regression grade & MR volumetry

  2. Acute/ late toxicities

    Time frame: preoperative CCRT to 3 months after surgery

    To evaluate the acute and late toxicities

Sponsors and collaborators

Lead sponsor

National Cancer Center, Korea

Other Gov

Registry information

Official study title

Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer: Phase II Multi-institutional Study

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
May 25, 2010
Registry last updated
Apr 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.